| Prev Close | 26.03 |
| Open | 26.24 |
| Day Low/High | 25.02 / 26.95 |
| 52 Wk Low/High | 14.03 / 46.99 |
| Volume | 1.05M |
| Avg Volume | 786.10K |
| Exchange | NASDAQ |
| Shares Outstanding | 51.99M |
| Market Cap | 1.29B |
| EPS | -2.10 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
Cempra To Present Solithromycin At FDA Antimicrobial Drugs Advisory Committee Meeting On November 4, 2016
FDA currently reviewing NDAs for IV and oral solithromycin for community-acquired bacterial pneumonia, with PDUFA dates in late December
Cempra Announces European Medicines Agency Validates MAA For Solithromycin For Treatment Of CABP
Formal review of solithromycin by EMA now underway
Perilous Reversal Watch: Cempra (CEMP)
Trade-Ideas LLC identified Cempra (CEMP) as a "perilous reversal" (up big yesterday but down big today) candidate
Cempra (CEMP) Is Today's Strong On High Volume Stock
Trade-Ideas LLC identified Cempra (CEMP) as a strong on high relative volume candidate
Cempra To Report Second Quarter 2016 Financial Results
Management to host webcast and conference call on August 1, 2016 at 4:30 p.m. EDT
Antibiotic for Treatment of Superbugs Could Send Cempra Shares Soaring
Solithera is well along in the FDA approval process, and if the antibiotic is approved, the North Carolina-based company will have a potential blockbuster drug.
Cempra (CEMP) Is Today's Strong On High Volume Stock
Trade-Ideas LLC identified Cempra (CEMP) as a strong on high relative volume candidate
Cempra Announces FDA Acceptance Of Solithera™ New Drug Applications In The Treatment Of Community-Acquired Bacterial Pneumonia
PDUFA Dates of December 27 and 28, 2016
Cempra Submits Marketing Authorization Application To EMA For Solithromycin In The Treatment Of Community-Acquired Bacterial Pneumonia
Marketing Authorization Application (MAA) submitted for Europe for intravenous and for oral capsules
Commit To Purchase Cempra At $15, Earn 36.5% Annualized Using Options
Investors considering a purchase of Cempra Inc shares, but cautious about paying the going market price of $18.19/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2017 put at the $15 strike, which has a bid at the time of this writing of $3.20.
Strong On High Volume: Cempra (CEMP)
Trade-Ideas LLC identified Cempra (CEMP) as a strong on high relative volume candidate
Today's Dead Cat Bounce Stock: Cempra (CEMP)
Trade-Ideas LLC identified Cempra (CEMP) as a "dead cat bounce" (down big yesterday but up big today) candidate
Cempra (CEMP) Stock: Weak On High Volume Today
Trade-Ideas LLC identified Cempra (CEMP) as a weak on high relative volume candidate
Cempra (CEMP): Today's Weak On High Volume Stock
Trade-Ideas LLC identified Cempra (CEMP) as a weak on high relative volume candidate
Cempra (CEMP) Strong On High Relative Volume Today
Trade-Ideas LLC identified Cempra (CEMP) as a strong on high relative volume candidate
Cempra To Report First Quarter 2016 Financial Results
Management to host webcast and conference call on May 2, 2016 at 8:00 a.m. ET
